Citations

Clear

798 citation(s) found for "Levy, E".

Health conditions and RSV-related Pediatric Intensive Care Unit admissions in children during their second RSV season
Zambrano, Laura, Newhams, Margaret M., Payne, Amanda B., Orzel-Lockwood, Amber O., Halasa, Natasha B., Calixte, Jemima, Chiotos, Kathleen, Crandall, Hillary , Cameron, Melissa A. , Coates, Bria M. , Michelson, Kelly N., Schuster, Jennifer E., Nofziger, Ryan A. , Chauhan, Jigar C., Maamari, Mia , Kong, Michele, Martine, Lora M., Guzman‐Cottrill, Judith A. , Bhumbra, Samina S. , Irby, Katherine , Staat, Mary Allen, Bradford, Tamara T. , Wellnitz, Kari, Ml, Stockwell, Zinter, Matt, Hymes, Saul, Levy, Emily R. , Biggs, Austin , Lindsey, Katherine, Campbell, Angela P., Simeone, Regina M. , Zambrano, Laura D. , Newhams, Margaret M. , Payne, Amanda B. , Halasa, Natasha , Calixte, Jemima M., Maddux, Aline B. , Chiotos, Kathleen , Kamidani, Satoshi , Zerr, Danielle M. , Gertz, Shira J. , Michelson, Kelly Nicole , Schuster, Jennifer E. , Chauhan, Jigar , Shein, Steven L. , Kong, Michele , Hume, Janet R. , Staat, Mary Allen , Wellnitz, Kari , Zinter, Matt S. , Schwartz, Stephanie P. , Hymes, Saul, Lindsey, Katherine N. , Campbell, Angela P. , Randolph, Adrienne G.

Mayo Clinic

No container title available | June 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.26.26356705 Get It

Abstract Importance Respiratory syncytial virus (RSV) hospitalization rates are highest among children <2 years of age. RSV immunization with infant monoclonal antibody or maternal vaccine is recommended to protect all U.S. infants in their first RSV season. For certain high-risk children aged 8−19 months entering their second RSV season, the monoclonal antibody nirsevimab is recommended. Little is known regarding preexisting health conditions as risk factors for RSV-associated respiratory failure in children during their second season. Objectives To describe children admitted to the pediatric intensive care unit (PICU) for RSV during their second RSV season by preexisting health conditions, and to compare demographic and clinical characteristics across groups. Design, Setting, and Participants Surveillance registry of children 8-<24 months old admitted to the PICU in 30 pediatric hospitals in the 2023-2024/2024-2025 RSV seasons. All children had an RSV-positive respiratory sample and received respiratory support with high flow nasal cannula, noninvasive ventilation, or invasive mechanical ventilation (IMV). Exposure Preexisting health conditions potentially increasing risk of severe RSV disease. Main Outcomes and Measures Patients were classified into four mutually exclusive groups by preexisting health conditions: 1) U.S. nirsevimab eligible criteria, 2) other identified RSV risk conditions (with some evidence of increased risk for severe RSV), 3) other preexisting conditions, and 4) no preexisting conditions. Patient demographic characteristics and level of respiratory support received were compared. Results Among 574 children: 47 (8.2%) had U.S. nirsevimab eligibility criteria, 76 (13.2%) had other RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. A higher proportion of children with nirsevimab eligibility factors (40.4%) than those with other identified RSV risk conditions (17.1%) required IMV, which was higher than other (10.4%) or no (5.9%) preexisting health conditions (p trend <0.001). Conclusions and Relevance Approximately 20% of children admitted to the PICU with severe RSV were in the defined groups that met U.S. nirsevimab-eligibility criteria or that had an identified RSV risk condition associated with known risk for severe RSV. A considerable proportion of both groups of children required IMV for respiratory support. These findings may help inform future deliberations regarding U.S. second season nirsevimab-eligibility recommendations. Key Points Question What preexisting health conditions are present in children aged 8–<24 months admitted to the pediatric intensive care unit for severe RSV disease in their second RSV season and how do clinical outcomes differ? Findings Among 574 children, 8% were eligible for nirsevimab in the U.S. and 13% had other preexisting conditions with known risk for severe RSV. Children with preexisting conditions, particularly those eligible for nirsevimab, were more likely to require invasive mechanical ventilation than those without. Meaning These findings may inform future deliberations regarding which children in their second RSV season might benefit from RSV preventive products.
Prior Hip Arthroscopy Is Associated With Inferior Outcomes After Total Hip Arthroplasty: A Propensity‐Matched Study
Cabarcas, Brandon C. , Kang, Louis , Ahmad, Rana A. , Levy, Bruce A. , Sierra, Rafael J. , Trousdale, Robert T. , Krych, Aaron J. , Taunton, Michael J., Hevesi, Mario , Kang, Louis S , Cabarcas, Brandon , Krych, Aaron J , Sierra, Rafael J , Hevesi, Mario , Taunton, Michael J.

Mayo Clinic

Arthroscopy | June 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70382 | PMID 42365478 Get It

Purpose To investigate outcomes among patients undergoing total hip arthroplasty after hip arthroscopy (HA‐THA) compared with a matched cohort undergoing primary THA without prior arthroscopy (Only‐THA). Methods Patients who underwent THA after primary hip arthroscopic labral repair from 2009 to 2022 at a single institution were identified. Cases were propensity‐matched 1:4 to primary THA controls by age at THA, sex, body mass index (BMI), surgical approach, and year of surgery. At minimum 2‐year follow‐up, patient‐reported outcomes (PROs)—Forgotten Joint Score (FJS), modified Harris Hip Score (mHHS), and Hip Disability and Osteoarthritis Outcome Score Pain (HOOS‐Pain)—were analyzed. Results Sixty‐two hips (age: 47.5 ± 9.3 years, BMI: 29.7 ± 6.2 kg/m 2 ) were matched to 248 Only‐THA hips (age: 47.9 ± 10 years, BMI: 29.5 ± 5.8 kg/m 2 ). Although both HA‐THA and Only‐THA patients showed significant ( P < .001) postoperative improvements in PROs, HA‐THA patients reported significantly lower postoperative FJS, mHHS, HOOS‐Pain, and inferior Visual Analog Scale pain scores ( P < .001) compared with Only‐THA controls. A cohort‐specific minimal clinical important difference for mHHS was calculated as 9.6 points, with 75.7% of HA‐THA and 87.5% Only‐THA patients achieving this threshold ( P = . 077). At mean 6.6 ± 3.3 years follow‐up, HA‐THA patients with preoperative Tönnis grades 1 reported significantly decreased FJS, mHHS, and HOOS‐Pain compared with HA‐THA patients with preoperative Tönnis grade 2‐3 ( P ≤ .05). HA‐THA patients with Tönnis grade 1 also exhibited worse PROs ( P < .001) compared with Only‐THA controls. Although there were no differences in complication rates between HA‐THA and Only‐THA patients (8% vs. 5%, P = .49), all‐cause reoperation was greater amongst HA‐THA (10% vs. 2%, P = .01). Conclusions Patients undergoing THA after prior hip arthroscopy showed modestly inferior subjective outcomes at mid‐term follow up compared with an age‐matched cohort without prior arthroscopy. Although both groups showed meaningful improvement, a smaller proportion of HA‐THA patients achieved the cohort‐specific MCID for mHHS compared with Only‐THA controls. Level of Evidence Level III, retrospective cohort study.
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD
A, Prera Vilaseca, Bilodeau, Philippe-Antoine, Hellmann, Mark , Jiang, Mulan , Chen, John J., Pittock, Sean J., Levy, Michael, Flanagan, Eoin P., Levy, Michael , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Levy, Michael , Vilaseca, Andreu, Lotan, Itay , Hellmann, Mark, Pittock, Sean J. , Flanagan, Eoin P. , Kister, Ilya

Mayo Clinic

JAMA Neurology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.1850 | PMID 42295768 Get It

This case series describes multicenter experience with interleukin 6 (IL-6) receptor blockers used during attacks in aquaporin 4–immunoglobulin G–positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD).
How to Set Anterior and Posterior Tibial Translation for Combined Anterior Cruciate Ligament and Posterior Cruciate Ligament Reconstruction
Rechter, Griffin R. , Khan, Abid M. , Tagliero, Adam J. , Kannan, Abhishek , Levy, Brooke R., Krych, Aaron J. , Levy, Bruce A. , Kannan, Abhishek S , Krych, Aaron J , Tagliero, Adam

Mayo Clinic

Arthroscopy Techniques | June 13, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1002/atn2.70113 | PMID 42499864 Get It

Abstract Anterior and posterior cruciate ligament (ACL and PCL) reconstruction poses the risk of residual anterior or posterior tibial translation, respectively. As a result, patients may have residual knee instability and laxity, which can contribute to poor outcomes and graft failure. Ultimately, minimizing anterior and posterior tibial translation through proper ACL and PCL graft tensioning has the potential to improve clinical and functional outcomes in the setting of ACL and PCL reconstruction surgery. This technique aims to show a reproducible method for “setting” anterior and posterior tibial translation in the setting of ACL and PCL reconstructions.
Tocilizumab as Add-on Therapy for Severe Attacks in NMOSD and MOGAD: A Multicenter Retrospective Case Series (P3-1.009)
Flanagan, Eoin P., Vilaseca, Andreu, Bilodeau, Philippe-Antoine, Jiang, Mulan , Said, Yana , Chen, Haiwen , Chen, John J., Pittock, Sean J., Sotirchos, Elias, Levy, Michael, Flanagan, Eoin P. , Vilaseca, Andreu , Bilodeau, Philippe-Antoine, Filippatou, Angeliki , Pittock, Sean J. , Sotirchos, Elias S. , Levy, Michael , Kister, Ilya

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217046 Get It

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)
Bilodeau, Philippe-Antoine, Devlin, Michael, Bhattacharyya, Shamik, Salky, Rebecca, Mendoza, Juan Sebastian, Friede, Tim, Bennett, Jeffrey, Cree, Bruce, Palace, Jacqueline, Levy, Michael, Fujihara, Kazuo, Kim, Ho Jin, Flanagan, Eoin , Matiello, Marcelo, Paul, Friedemann, Vishnevetsky, Anastasia , Bhattacharyya, Shamik , Friede, Tim , Cree, Bruce , Palace, Jacqueline , Levy, Michael , Fujihara, Kazuo , Kim, Ho Jin , Flanagan, Eoin P. , Matiello, Marcelo , Paul, Friedemann

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217044 Get It

Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial (PL5.006)
Levy, Michael, Flanagan, Eoin , Kümpfel, Tania, Marignier, Romain, Fujihara, Kazuo, Hemingway, Cheryl, Stokmaier, Daniela, Klingelschmitt, Gaëlle, Büdingen, H.-Christian von, TANAKA, SAYURI, Friedemann, Paul, Levy, Michael , Flanagan, Eoin P. , Kümpfel, Tania , Marignier, Romain , Fujihara, Kazuo , Hemingway, Cheryl , Büdingen, H.-Christian von, Li, Li

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217915 Get It

Headache Specialists versus Artificial Intelligence for Clinical Literature Summarization: A Critical Evaluation and Comparison (P9-15.009)
Lozano, Alejandro, Yang, Ping‐Hao , Robertson, Carrie, Stern, Jennifer, Purdy, Allan, Zhang, Pengfei, Orlova, Yulia, Fermo, Olga, Hranilovich, Jennifer, Schwedt, Todd, Yeung-Levy, Serena, Chiang, Chia‐Chun , Ihara, Keiko , Yuan, Hsiangkuo , Orlova, Yulia , Fermo, Olga , Hranilovich, Jennifer A. , Cohen, Fred , Schwedt, Todd J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215849 Get It

Long-term Efficacy and Safety of Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Final Analysis of the Phase 3 CHAMPION-NMOSD Trial (P7-1.012)
Pittock, Sean, Barnett, Michael, Bennett, Jeffrey, Berthele, Achim, Seze, Jérôme de, Levy, Michael, Oreja-Guevara, Celia, Palace, Jacqueline, Paul, Friedemann, Allen, Kerstin, Parks, Becky, Kim, Ho Jin, Pittock, Sean J. , Barnett, Michael , Bennett, Jeffrey, Berthele, Achim , Seze, Jerome De , Levy, Michael , Nakashima, Ichiro , Oreja‐Guevara, Celia , Palace, Jacqueline , Paul, Friedemann , Pozzilli, Carlo , Allen, Kerstin , Parks, Becky , Kim, Ho Jin

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000215493 Get It

BRAF-altered glioma in adults and children: A Society for Neuro-Oncology (SNO) and European Society for Neuro-Oncology (EANO) consensus review on clinical management and future directions
Schreck, Karisa C, Fuente, Macarena I de la, Fat, Mary Jane Lim, Maas, S L, Levy, Jean M Mulcahy, Lombardi, G , Perrault, Sébastien, Petritsch, Claudia , Aldape, Kenneth, Chang, Susan M, Holdhoff, Matthias, Kazda, Tomas, Rhun, Emilie Le, Minniti, Giuseppe, Mueller, Sabine, Preusser, M, Smits, Marion, Weller, Michael, Wen, Patrick Y, Bent, Martin van den, Geurts, Marjolein, Lombardi, Giuseppe , Maas, Sybren L. N. , Schreck, Karisa C. , Levy, Jean M. Mulcahy , Chang, Susan M. , Duerinck, Johnny , Holdhoff, Matthias , Kazda, Tomáš , Rhun, Émilie Le , Minniti, Giuseppe , Mishra, Mark V. , Mueller, Sabine , Padovan, Marta , Preusser, Matthias , Smits, Marion , Weller, Michael , Bent, Martin J. van den , Geurts, Marjolein

Mayo Clinic

Neuro-Oncology | June 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag135 | PMID 42261252 Get It

Abstract Oncogenic BRAF alterations occur in a subset of diffuse gliomas across WHO grades and are increasingly identified through modern molecular diagnostics. In addition to standard glioma therapies, targeted treatments are available for patients with BRAF-altered glioma supported by variable evidence spanning randomized trials, single-arm studies, and real-world evidence. This joint consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO) synthesizes current knowledge on the diagnosis and management of BRAF-altered gliomas across age groups, tumor grades, and lines of therapy. Particular emphasis is placed on expert consensus in clinical scenarios where high-quality trial evidence remains limited. The review addresses rationale testing for BRAF alterations, selection, and monitoring of targeted therapies, management of treatment-related toxicities, approaches to resistance, and priorities for future research. It aims to provide practical, evidence-based guidance for clinicians while highlighting gaps to inform prospective studies.